Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|April 18, 2017
Managing Effective Specialty Drug Distribution
Author(s)Lauren Santye, Assistant Editor
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses optimal support for distribution of specialty therapies.
Advertisement
Kevin James, RPh, MBA, vice president of Payer Strategy at US Bioservices, discusses optimal support for distribution of specialty therapies.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement